Our free daily oncology focused e-news service.
Subscribe» | Search Archives»
(Novartis) Nov 25, 2014 - Novartis announced today that the US Food and
Drug Administration (FDA) has extended their priority review period by
up to three months for the new drug application (NDA) of LBH589
(panobinostat) in combination with bortezomib and dexamethasone for
patients with previously treated multiple myeloma.
read corporate press release »
(Reuters) Nov 24, 2014 - Genentech, U.S. biotech unit of Roche Holding,
faces growing pressure over a decision to allow only a handful of
distributors to supply three of the world's most widely used cancer
drugs, a move that prominent hospitals say will create delays and raise
read article »
(Wall Street Journal) Nov 24, 2014 – The incidence of melanoma has been rising for at least 30 years, according to the American Academy of Dermatology, and several new drugs in recent years have improved survival rates in advanced cases.
read article (paid subscription required) »
News Story Commentary By Academic and Community Oncologists
Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.
OBR Job Board
NCCN has posted 1 new job.
Bayer Biopharmaceuticals, Inc. has posted 20 jobs.
Ipsen Biopharmaceuticals, Inc. has posted over 50 jobs.